Search clinical trials for: Tolcapone Modified Release Prototype

Total 109 results

KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Healthy

United Kingdom
Corino Therapeutics, Inc.
Quotient Sciences

Completed

A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone

Healthy Volunteers

United Kingdom
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Amgen

Completed

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

Healthy Volunteers

United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Genzyme, a Sanofi Company

Completed

Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone

Healthy

United States
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Healthy

Singapore
Mansoura University

Unknown

Evaluation of Posterior Component Separation Modified TAR Technique "Transversus Abdominids Release" in the Treatment of Parastomal Hernia

TAR Technique

Egypt
UNION therapeutics

Active, not recruiting

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

Skin Diseases | Atopic Dermatitis

Poland, United States, Hungary, Germany
UNION therapeutics

Completed

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis (IASOS)

Skin Diseases | Psoriasis

United Kingdom, Poland, United States, Germany
Lung Biotechnology PBC

Completed

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Czechia, Germany, Ireland, Romania
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
Lung Biotechnology PBC

Completed

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Ireland
Noorik Biopharmaceuticals AG

Terminated

A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Cirrhosis | Ascites | Portal Hypertension

Spain
Rock Creek Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations

Pharmacokinetics of Anatabine

United Kingdom
Icahn School of Medicine at Mount Sinai
U.S. Department of Education

Completed

Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury

Neuropathic Pain | Spinal Cord Injury

United States
Asan Medical Center

Completed

The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo (BPPV)

Benign Paroxysmal Positional Vertigo

Korea, Republic of
Boehringer Ingelheim

Completed

Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Cerebrovascular Accident

Taiwan
Diurnal Limited

Active, not recruiting

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency (CHAMPAIN)

Primary Adrenal Insufficiency

Germany, United Kingdom
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

Liver Transplantation

Korea, Republic of
Lung Biotechnology PBC

Completed

Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Belgium, Czechia, Germany, Ireland, Romania
Lung Biotechnology PBC

Completed

A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

Pulmonary Arterial Hypertension

United States, Ireland, Belgium
The Adelaide and Meath Hospital, incorporating...

Unknown

Optimising Steroid Replacement in Patients With Adrenal Insufficiency

Adrenal Insufficiency

Ireland
Velicept Therapeutics, Inc.

Completed

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (VEL-2001)

Overactive Bladder

United States
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Galderma R&D

Completed

ORCA - Oracea® for Rosacea: A Community-based Assessment

Rosacea

United States
Diurnal Limited
National Institutes of Health (NIH)

Completed

Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH

Congenital Adrenal Hyperplasia | Adrenal Insufficiency | Endocrine Disease

United States
Abbott
Eilaf

Completed

Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER) (CLOSER)

Respiratory Tract Infection

Egypt, Saudi Arabia
Lung Biotechnology PBC

Withdrawn

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

Pulmonary Arterial Hypertension
Lung Biotechnology PBC

Completed

Beraprost-314d Added-on to Tyvaso® (BEAT) (BEAT)

Pulmonary Arterial Hypertension

United States, Israel
Diurnal Limited

Enrolling by invitation

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia

United States, France, Japan
Lundquist Institute for Biomedical Innovation at...
Lung Biotechnology PBC

Completed

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

Healthy

United States
Lung Biotechnology PBC

Terminated

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension (BEAT OLE)

Pulmonary Arterial Hypertension

United States, Israel
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

Healthy

Singapore
Diurnal Limited

Completed

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia (CONnECT)

Congenital Adrenal Hyperplasia

France, United States, Japan
Pfizer

Completed

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

Healthy

United States
Ulla Feldt-Rasmussen

Unknown

Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism (PlenadrEMA)

Adrenal Insufficiency
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Mundipharma Research Limited

Terminated

A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

Polymyalgia Rheumatica

United Kingdom
Labatec Pharma SA

Unknown

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Osteoporosis, Postmenopausal

Switzerland
Diurnal Limited
National Institutes of Health Clinical Center (CC)

Completed

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

Adrenogenital Syndrome | Congenital Adrenal Hyperplasia | 21-Hydroxylase Deficiency

United States
University of Manchester
King's College London; Northern Care Alliance NHS Foundation Trust; University... and other collaborators

Completed

The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms (BeneMin)

Schizophrenia and Disorders With Psychotic Features

3

Subscribe